The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia
Primary Purpose
Type 1 Diabetes Mellitus With Hypoglycemia
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
SodiumChloride
Sodium Lactate
Sponsored by
About this trial
This is an interventional basic science trial for Type 1 Diabetes Mellitus With Hypoglycemia focused on measuring type 1 diabetes mellitus, impaired awareness of hypoglycemia, lactate, MR spectroscopy
Eligibility Criteria
Inclusion Criteria:
- Diabetes duration ≥ 1 year
- Age: 18-50 years
- Body-Mass Index: 18-30 kg/m2
- HbA1c: 42-75 mmol/mol (6-9%)
- Outcome Clarke questionnaire: 0-1 or >=3
- Blood pressure: <160/90 mmHg
Exclusion Criteria:
- Inability to provide informed consent
- Use medication other than insulin, except for oral contraceptives or stable thyroxin supplementation therapy
- Presence of any other medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event, known liver disease, anxiety disorders or a history of panic attacks.
- Microvascular complications of T1DM: Proliferative retinopathy, Symptomatic diabetic neuropathy (including autonomic neuropathy), Nephropathy; clinical/overt albuminuria or an estimated glomerular filtration rate <60ml/min/1.73m2
- MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)
Sites / Locations
- Radboud umc
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Lactate infusion
NaCl infusion
Arm Description
Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
As a control condition, subjects will receive intravenous NaCl infusion
Outcomes
Primary Outcome Measures
the effect of intravenous lactate administration, compared to placebo, on brain lactate concentrations during euglycemia and hypoglycemia in patients with T1DM and normal awareness of hypoglycemia
the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia
Secondary Outcome Measures
The changes in counterregulatory hormone and to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia
The changes in and symptoms to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia
The changes in brain pH in response to intravenous lactate administration, compared to placebo
Changes in immune cell composition capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo
Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo
Full Information
NCT ID
NCT03286816
First Posted
November 23, 2016
Last Updated
September 14, 2017
Sponsor
Radboud University Medical Center
Collaborators
Dutch Diabetes Research Foundation, European Foundation for the Study of Diabetes
1. Study Identification
Unique Protocol Identification Number
NCT03286816
Brief Title
The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia
Official Title
The Effect of Intravenous Lactate Administration on Brain Lactate Concentrations and pH During Euglycemia and Hypoglycemia in Patients With Type 1 Diabetes With and Without Impaired Awareness of Hypoglycemia
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
November 2016 (undefined)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
August 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
Dutch Diabetes Research Foundation, European Foundation for the Study of Diabetes
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with type 1 diabetes (T1DM) who are unable to perceive symptoms of hypoglycemia, referred to as impaired awareness of hypoglycemia (IAH), are at very high risk of severe hypoglycemia. IAH affects approximately 25% of patients with T1DM. Brain lactate may be involved in the development of IAH. A recent study indicated increased brain lactate utilization during hypoglycemia in T1DM patients with IAH, which did not occur in patients with normal awareness of hypoglycemia (NAH). Conversely, administration of lactate to patients with NAH has been shown to attenuate counterregulatory hormone responses to and symptomatic awareness of hypoglycemia, thus causing a situation that resembles IAH. It has, however, not been demonstrated whether the excess of lactate is actually taken up or metabolized by the brain, and if so whether this occurs under euglycemic or hypoglycemic conditions or both.
This project consists of two related studies. The objective of part 1 is to investigate the effect of elevated plasma lactate levels that are sufficient to impair awareness of hypoglycemia on brain lactate concentrations during euglycemia and hypoglycemia in T1DM patients with NAH. The objective of part 2 is to compare the effect of exogenous lactate on brain lactate concentrations between T1DM patients with NAH and T1DM patients with IAH.
Furthermore, this study aims to determine the effect of acute hypoglycemia on the inflammatory function and composition of peripheral blood mononuclear cells.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus With Hypoglycemia
Keywords
type 1 diabetes mellitus, impaired awareness of hypoglycemia, lactate, MR spectroscopy
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lactate infusion
Arm Type
Experimental
Arm Description
Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
Arm Title
NaCl infusion
Arm Type
Placebo Comparator
Arm Description
As a control condition, subjects will receive intravenous NaCl infusion
Intervention Type
Drug
Intervention Name(s)
SodiumChloride
Intervention Type
Drug
Intervention Name(s)
Sodium Lactate
Primary Outcome Measure Information:
Title
the effect of intravenous lactate administration, compared to placebo, on brain lactate concentrations during euglycemia and hypoglycemia in patients with T1DM and normal awareness of hypoglycemia
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Title
the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Secondary Outcome Measure Information:
Title
The changes in counterregulatory hormone and to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Title
The changes in and symptoms to hypoglycemia in response to lactate infusion, compared to placebo, in patients with normal awareness of hypoglycemia
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Title
The changes in brain pH in response to intravenous lactate administration, compared to placebo
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Title
Changes in immune cell composition capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
Title
Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo
Time Frame
during stable euglycemia (40 min) and hypoglycemia (45 min)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diabetes duration ≥ 1 year
Age: 18-50 years
Body-Mass Index: 18-30 kg/m2
HbA1c: 42-75 mmol/mol (6-9%)
Outcome Clarke questionnaire: 0-1 or >=3
Blood pressure: <160/90 mmHg
Exclusion Criteria:
Inability to provide informed consent
Use medication other than insulin, except for oral contraceptives or stable thyroxin supplementation therapy
Presence of any other medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event, known liver disease, anxiety disorders or a history of panic attacks.
Microvascular complications of T1DM: Proliferative retinopathy, Symptomatic diabetic neuropathy (including autonomic neuropathy), Nephropathy; clinical/overt albuminuria or an estimated glomerular filtration rate <60ml/min/1.73m2
MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)
Facility Information:
Facility Name
Radboud umc
City
Nijmegen
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
23715622
Citation
De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes. 2013 Sep;62(9):3075-80. doi: 10.2337/db13-0313. Epub 2013 May 28.
Results Reference
background
PubMed Identifier
7926305
Citation
Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes. 1994 Nov;43(11):1311-7. doi: 10.2337/diab.43.11.1311.
Results Reference
background
PubMed Identifier
10907119
Citation
Maran A, Crepaldi C, Trupiani S, Lucca T, Jori E, Macdonald IA, Tiengo A, Avogaro A, Del Prato S. Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and type I diabetic subjects. Diabetologia. 2000 Jun;43(6):733-41. doi: 10.1007/s001250051371.
Results Reference
background
PubMed Identifier
26993070
Citation
Wiegers EC, Rooijackers HM, Tack CJ, Heerschap A, de Galan BE, van der Graaf M. Brain Lactate Concentration Falls in Response to Hypoglycemia in Patients With Type 1 Diabetes and Impaired Awareness of Hypoglycemia. Diabetes. 2016 Jun;65(6):1601-5. doi: 10.2337/db16-0068. Epub 2016 Mar 18.
Results Reference
background
PubMed Identifier
31001674
Citation
Wiegers EC, Rooijackers HM, van Asten JJA, Tack CJ, Heerschap A, de Galan BE, van der Graaf M. Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status. Diabetologia. 2019 Jun;62(6):1065-1073. doi: 10.1007/s00125-019-4862-9. Epub 2019 Apr 19.
Results Reference
derived
Learn more about this trial
The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia
We'll reach out to this number within 24 hrs